Latest Breaking News On - Event free survival - Page 4 : vimarsana.com

Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia

Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMadhuri vusirikalaCaroline yarbroughSandesh sethVenetoclax bclSergio giraltAvinash desaiDivision of hematologic malignanciesService at memorial sloan kettering cancer centerActinium pharmaceuticals incEuropean medicines agencyHans vitzthumlifesci advisorsCommittee for medicinal products human useClinical developmentFred hutchinson cancer research centerPrnewswire actinium pharmaceuticals inc

Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia

- Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical.

United statesMadhuri vusirikalaCaroline yarbroughSandesh sethHans vitzthumVenetoclax bclSergio giraltAvinash desaiLifesci advisorsActinium pharmaceuticals incDivision of hematologic malignanciesService at memorial sloan kettering cancer centerClinical developmentComplete remissionActinium pharmaceuticalsInvestor conference call

Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma

United statesSanta monicaFoster cityEl segundoJacquie rossKoji ogiwaraDaiichi sankyoWataru takasakiAnna padulaChristi shawRd divisionKite pharma incGilead sciencesGilead sciences incSustainable development of societyExchange commission

Gilead Sciences (GILD) Q2 2022 Earnings Call Transcript

GILD earnings call for the period ending June 30, 2022.

United statesUnited kingdomAndrew dickinsonChristi shawJacquie rossMerck keytrudaJohanna mercierMerdad parseyRandy dickinsonAmerican society of hematologyGilead sciencesEuropean commissionHealth technology assessmentsWelcome to gilead sciencesDanielo dayJoint procurement agreement

Seagen s (SGEN) ADCETRIS Plus Standard of Care Chemotherapy Demonstrates Superior EFS vs Standard of Care Alone in Children and Young Adults with Previously Untreated High-Risk Hodgkin Lymphoma

Seagen s (SGEN) ADCETRIS Plus Standard of Care Chemotherapy Demonstrates Superior EFS vs Standard of Care Alone in Children and Young Adults with Previously Untreated High-Risk Hodgkin Lymphoma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMccormick placeNew zealandBrentuximab vedotinSharonm castellinoDevelopment agreementNational clinical trials networkNational cancer instituteAmerican society of clinical oncologyChildren oncology groupNational institutes of healthEmory university school of medicineHodgkin lymphoma disease committee chairSeagen incDepartment of pediatricsStage development at seagen